Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Keytruda remains a major growth driver, with Q2 revenue up 9% year over year, but its looming loss of exclusivity is ...

MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.

Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson JNJ and MerckMRK are leading U.S. healthcare giants, making them natural peers for a head-to-head ...

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to ...

Meta stock plunged more than 9% after the Facebook parent company reported third-quarter results. A strong performance from ...

Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access . * Reflecting concerns, ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...